In this special edition of the View, Kim A. Eagle, MD, MACC, talks with Dharam J. Kumbhani MD, SM, FACC, Philippe Gabriel Steg, MD, FACC, and Payal Kohli, MD, FACC, about four of the major trials that were presented on Day 3 of the ESC Congress in Amsterdam on Sunday, Aug. 27.   The trials include ATTRIBUTE-CM (00:39), investigating the efficacy and safety of acoramidis in subjects with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM). MULISTARS (03:15), investigating patients presenting with ST segment elevation myocardial infarction (STEMI) and multi-vessel disease (MVD), comparing the safety and efficacy of immediate complete revascularization of all significant coronary lesions vs. culprit vessel only revascularization and staged percutaneous coronary intervention (PCI) of all significant coronary. ILLUMEN-IV (06:28) to demonstrate the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy as compared to an angiography-guided stent implantation strategy in achieving larger post-PCI lumen dimensions and improving clinical cardiovascular outcomes in patients with high-risk clinical characteristics and/or with high-risk angiographic lesions and the ARREST (10:02) Trial, comparing survival to hospital discharge between two standards of care after arrival at the hospital: emergency department-based standard ACLS resuscitation vs. early ECMO-facilitated resuscitation.  Subscribe to Eagle’s Eye View